Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 PixarBio, Particle Sciences Enter Manufacturing Agreement | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

PixarBio, Particle Sciences Enter Manufacturing Agreement

For 14-day post-surgical pain treatment

By: Betsy Louda

, Contract Pharma

PixarBio Corporation has announced an agreement with Particle Sciences to cGMP manufacture PixarBio’s NR14 product for clinical trials. NeuroRelease NR14 is a 14 day morphine replacement, and non-addictive pain platform for post-surgical pain.

 

In 2018, PixarBio will be able to apply to the US FDA for fast track approval through the CDER Breakthrough Therapy designation.

 

“Although the agreement covers our 14 day treatment, we also have a 7 and 3 day product in our pipeline that are not part of this agreement. We worked for over 3 years with PSI to put this agreement in place and look forward to a long term collaboration. I am confident that with the FDA’s fast track approval we can receive FDA clearance to market NR14 in late 2019,” said PixarBio’s chief executive officer, Frank Reynolds.

 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics